Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03012321 |
|
Recruitment Status :
Recruiting
First Posted : January 6, 2017
Last Update Posted : March 3, 2021
|
Sponsor:
Northwestern University
Collaborators:
AstraZeneca
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Maha Hussain, Northwestern University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2021 |
| Estimated Study Completion Date : | January 2022 |